OR WAIT null SECS
© 2023 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
WuXi's new facility in Philadelphia will manufacture CAR T-cell therapies and other cancer immunotherapies.
WuXi PharmaTech will soon begin construction of a new, 145,000-ft2 cGMP facility in Philadelphia, Pennsylvania for the manufacture of cell therapy products, the company announced on Mar. 12, 2015. This facility is designed for cell therapy products that contain viral vectors, such as chimeric antigen receptor T-cell (CAR T-cell) therapies, and will become WuXi's third cell-therapy manufacturing facility when it becomes operational by mid-2016.
The new facility will provide single-source contract development and cGMP manufacturing capabilities to support the rapidly growing cellular therapeutic industry's unique requirements, particularly the rapidly expanding demand for clinical studies and commercial supply, said the company in a press release. In the US, the new facility will expand upon WuXi's existing 16,000- ft2 cGMP cell therapy manufacturing facility and a 45,000- ft2 facility for the manufacturing of allogeneic and autologous cell-based therapeutics that is expected to be completed by mid-2015. These facilities will complement the company's current fully integrated facility for biological safety and lot-release testing in Philadelphia.
Source: WuXi PharmaTech